Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Direct
Mintz Viewpoints
Showing 1569 - 1576 of 12030 results
Energy & Sustainability Litigation Updates – June 2023
June 29, 2023| Article| Viewpoint
New ESG Requirements for Banks that Hold Public Funds May Raise Challenging Compliance Issues
June 29, 2023| Blog| Viewpoint
States, Industry Seek To Vacate WOTUS Rule As EPA Plans Quick Revision
June 29, 2023| News
New Levine Act Regulations – How Will They Affect You?
June 28, 2023| Advisory| Viewpoint
Better Late Than Never: Employers in Canada Should Review Their Termination of Employment Provisions
June 28, 2023| Blog| Viewpoint
Proposed Overhaul of HSR Premerger Notification Process
June 28, 2023| Blog| Viewpoint
FDA Opens a Pilot Program to Scrutinize Certain Laboratory Developed Tests, But Will It Generate Sufficient Interest?
June 28, 2023| Blog| Viewpoint
Cross-border Considerations for the Life Sciences Industry
June 27, 2023| Blog| Viewpoint
News & Press Releases
San Francisco Business Times featured Mintz’s new office lease in San Francisco at 525 Market St. The firm will be increasing its footprint in downtown by 50% to 29,000 square feet on a whole single floor with the new space.
Mintz advised the underwriters in connection with a $230 million public offering by Cogent Biosciences, Inc. of 25,555,556 shares of common stock, which includes 3,333,333 shares issued pursuant to the exercise in full by the underwriters of their option to purchase additional shares of common stock, offered at a public offering price of $9.00 per share. The aggregate gross proceeds to Cogent from this offering were approximately $230 million, including proceeds from the exercise in full by the underwriters of the option to purchase additional shares, before deducting underwriting discounts and commissions and other offering expenses.
Mintz advised the underwriters in connection with a $200 million public offering by Soleno Therapeutics, Inc. of 2,352,941 shares of its common stock at a price to the public of $85.00 per share. The gross proceeds to Soleno from the offering were approximately $200 million before deducting underwriting discounts and commissions and other offering expenses. In addition, Soleno granted the underwriters a 30-day option to purchase up to an additional 352,941 shares of its common stock at the public offering price.
Events
Mintz x The Engine: Supercharging Your IP Strategy with Trade Secrets
The Engine, 750 Main St. Cambridge, MA 02139
Podcasts
Mintz On Air: Practical Policies — A Private Equity Non-Compete Primer
July 15, 2025| Podcast|
Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|